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Abstract
Background: The aim of this study was to investigate the impact of ticagrelor mon-
otherapy following 1-month dual antiplatelet therapy (DAPT) after percutaneous cor-
onary intervention (PCI) for bifurcation lesions.
Methods: GLOBAL LEADERS was a randomized, superiority, all-comers trial compar-
ing 1-month DAPT with ticagrelor and aspirin followed by 23-month ticagrelor mon-
otherapy (experimental treatment) with standard 12-month DAPT followed by
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12-month aspirin monotherapy (reference treatment) in patients treated with a bio-
limus A9-eluting stent. The primary endpoint was a composite of all-cause death or
new Q-wave myocardial infarction (MI) at 2 years.
Results: Among the 15,845 patients included in this subgroup analysis, 2,498 patients
(15.8%) underwent PCI for at least one bifurcation lesion. The incidence of the primary
endpoint was similar between the bifurcation and nonbifurcation groups (4.7 vs. 4.0%,
p = .083). The experimental treatment had no significant effect on the primary endpoint
according to the presence/absence of a bifurcation lesion (bifurcation: hazard ratio
[HR]: 0.74, 95% confidence interval [CI]: 0.51–1.07; nonbifurcation: HR: 0.90, 95% CI:
0.76–1.07, p for interaction = .343), but was associated with significant reduction in def-
inite or probable stent thrombosis (p for interaction = .022) and significant excess of
stroke (p for interaction = .018) when compared with the reference treatment.
Conclusions: After PCI for bifurcation lesions using 1-month of DAPT followed by
ticagrelor monotherapy for 23 months did not demonstrate explicit benefit regarding
all-cause death or new Q-wave MI as in the overall trial.
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1 | INTRODUCTION
Bifurcation lesions are associated with a lower rate of procedural success
and a higher risk of complications compared to nonbifurcation lesions in
patients treated with percutaneous coronary intervention (PCI).1,2
A number of randomized controlled trials have investigated the optimal
intervention strategy in patients with bifurcation lesions and showed no
benefit in terms of clinical outcomes for the systematic two-stent
approach versus main branch-only stenting with provisional stenting of
the side branch.2 Therefore, this provisional side branch stenting strategy
is the recommended treatment of bifurcation lesions with a Class IA rec-
ommendation in current guidelines.3 In 5–25% of cases, a second stent
for the side branch may be needed4–6; however, the best two-stent
technique to use in these situations remains debatable.3
The complexity and the numerous subtypes of two-stent techniques
render their comparison difficult. For that reason, the European bifurca-
tion club introduced the Main, Across, Distal, Side (MADS) classification
to standardize reports that allow comparison between studies and facili-
tate interpretation of published results in the evolving literature.7,8 In the
GLOBAL LEADERS trial, the dedicated electronic case record form (e-
CRF)-based MADS classification was achieved in all site-reported bifur-
cation lesions, which represents a unique opportunity to analyze a cohort
stratified for the presence of bifurcation lesions within a large contempo-
rary PCI trial.9
In terms of antiplatelet therapy, although the increased complexity
of PCI including two-stent technique for bifurcation lesions represent a
driver for favoring more prolonged dual antiplatelet therapy (DAPT),
the evidence regarding the optimal duration of DAPT based on the
complexity of intervention is limited, especially due to the low preva-
lence of bifurcation PCI in the previous clinical trials.10,11 Furthermore,
the role of potent P2Y12 inhibitors after bifurcation PCI is uncertain.
In this prespecified subgroup analysis of the primary endpoint such
as all-cause death and new Q-wave myocardial infarction (MI) from
the GLOBAL LEADERS trial,12 we sought to investigate the impact of
ticagrelor monotherapy following 1-month DAPT after bifurcation PCI.
2 | METHODS
2.1 | The GLOBAL LEADERS trial
The design and main results of the GLOBAL LEADERS trial have been
published previously.13 Briefly, it was a prospective, multicenter, ran-
domized, open-label, superiority trial comparing two antiplatelet regi-
mens in 15,991 all-comers patients who were exclusively treated with
a biolimus A9-eluting stent for stable coronary artery disease or acute
coronary syndromes.
Patients were randomly assigned in a 1:1 fashion to 1-month DAPT
with aspirin and ticagrelor followed by 23 months of ticagrelor mon-
otherapy (experimental treatment), or standard DAPT with aspirin plus
either clopidogrel (for patients with stable coronary artery disease) or
ticagrelor (for patients with acute coronary syndromes) for 12 months,
followed by aspirin monotherapy for 12 months (reference treatment).
Regarding the primary endpoint of all-cause death or new Q-wave MI
at 2 years, the overall trial failed to demonstrate the superiority of
experimental treatment compared with the reference treatment (3.81%
in the experimental treatment vs. 4.37% in the reference treatment,
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p = .073), although at 1 year, the superiority of experimental treatment
was demonstrated (1.95 vs. 2.47%, p = .028).
The trial was approved by the institutional review board at each
investigating center. The study followed the ethical principles of the
Declaration of Helsinki. All the participants provided written informed
consent at the time of participation in the trial. The trial is registered
with ClinicalTrials.gov, number NCT01813435.
2.2 | Study population and data collection
According to the all-comers concept, only a limited number of inclu-
sion and exclusion criteria were applied in the GLOBAL LEADERS trial
(Data S1).
In this prespecified subgroup analysis of primary endpoint, patients
undergoing bifurcation PCI were identified from the dedicated e-CRF-
based MADS classification reported by investigators. Bifurcation lesions
were defined by investigators in accordance with the practical definition
of the European Bifurcation Club,7 as “a coronary artery narrowing occur-
ring adjacent to, and/or involving the origin of a significant side branch.”
All bifurcation PCIs were classified whether treated with one- or two-stent
technique using the results of the MADS classification. Three-stent tech-
niques such as “extended V” and “trouser legs and seat” were included in
the two-stent technique. The stenting technique for trifurcation lesion is
not covered by the MADS classification, therefore trifurcation was identi-
fied according to the definition of SYNTAX score.14 The choice of bifurca-
tion treatment technique was left to the discretion of the operators.
As many as seven on-site monitoring visits were done at individual
sites, with 20% of reported events checked against source documents.
Additionally, the trial was monitored for event underreporting and
event definition consistency. However, no overall central independent
adjudication of clinical events was implemented.
2.3 | Endpoint definitions
The primary endpoint was the composite of all-cause death or new Q-
wave MI up to 2 years after randomization. Deaths from any cause
were ascertained without adjudication,15 due to the fact that the sur-
vival data were derived from thorough site reports and search for vital
status obtained from public domains. Q-wave MI was centrally adjudi-
cated and defined in compliance with the Minnesota classification
(new major Q-QS wave abnormalities) or by the appearance of a new
left bundle branch block in conjunction with abnormal biomarkers.
The secondary endpoints included individual components of the pri-
mary endpoint (all-causedeath andnewQ-waveMI); composite of all-cause
death, stroke, or new Q-wave MI; any stroke; ischemic stroke; any MI; any
revascularization; target vessel revascularization (TVR); definite stent
thrombosis (ST); definite or probable ST16; and bleeding defined according
to the Bleeding Academic Research Consortium criteria (type 3 or 5) up to
2 years.17
The third universal definition of MI was the recommended criteria
to report MI.18 Composite endpoints were analyzed hierarchically.
Individual components were reported nonhierarchically.19
2.4 | Statistical analysis
Clinical outcomes were compared between patients treated for at
least one bifurcation lesion versus patients not treated for any bifur-
cation lesion (bifurcation vs. nonbifurcation).
Thereafter, the effect of experimental versus reference anti-
platelet therapy on clinical outcomes according to presence/absence
of bifurcation PCI was estimated with a Cox regression model.
Eventually, we did a subgroup analysis of the primary endpoint
only in patients treated for at least one bifurcation lesion with tests
for treatment–by subgroup interaction according to the prespecified
baseline characteristics and the type of stenting technique such as
one-stent and two-stent techniques. Due to the absence of classifica-
tion for trifurcation PCI according to the MADS classification, patients
with trifurcation PCI were excluded from the analysis comparing one-
versus two-stent technique.
Categorical variables were compared with the χ2 test or Fisher's exact
test. Continuous variables were compared with Student's t test or Mann–
Whitney U test for nonnormally distributed data. Composite endpoints
were calculated using time to first of any of the composite event(s) per
patient. Patients started being at risk on the day of index PCI or if no pro-
cedure was performed on the day of randomization. Survival curves were
constructed using Kaplan–Meier estimates, and the log-rank test was used
to compare between-group differences. Landmark analyses were per-
formed with prespecified cutoffs at 30 days (at the time of the planned
date of discontinuation of aspirin in the experimental treatment) and 1 year
(at the time of the planned dates of discontinuation of a P2Y12 inhibitor
in the reference treatment). In total, there were six outpatient protocol
visits at 30 days, 3, 6, 12, 18, and 24 months. A two-sided p value of less
than .05 was considered to indicate statistical significance. All statistical
analyses were done in SPSS (version 25.0.0, IBM, New York, NY).
3 | RESULTS
The GLOBAL LEADERS trial recruited a total of 15,991 patients,13 of
whom 146 patients were excluded from this analysis (Figure 1), leav-
ing 15,845 patients of which 2,498 patients (15.7%) underwent PCI
for at least one bifurcation lesion and 7 patients (0.04%) at least one
trifurcation lesion. Among the patients with at least one bifurcation
lesion, 2002 (80.1%) were treated with PCI using a one-stent tech-
nique and 489 (19.6%) using a two-stent technique (Figure 1).
3.1 | Clinical outcomes: Bifurcation versus
nonbifurcation groups
Patients in the nonbifurcation group had a higher body mass index
and higher prevalence of diabetes mellitus or previous revasculariza-
tion, whereas patients in the bifurcation group more often presented
with acute coronary syndrome (Table 1). In terms of procedural char-
acteristics, patients in the bifurcation group as expected had more
lesions, stents, and longer total stent length per patient.
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In terms of the primary endpoint (a composite of all-cause death or new
Q-wave MI) at 2 years, there was a trend toward a higher incidence in the
bifurcation group compared with the nonbifurcation group (4.72 vs. 3.98%,
hazard ratio (HR): 1.19, 95% confidence interval [95% CI]: 0.98–1.46,
p = .083), a difference driven by the significantly higher incidence of newQ-
wave MI in the bifurcation group (1.84 vs. 1.04%, HR: 1.78, 95% CI:
1.27–2.48, p = .001) (Table 2). The incidences of any revascularization at
2 years were higher in the bifurcation group versus nonbifurcation group
(11.21 vs. 9.19%, HR: 1.24, 95% CI: 1.09–1.41, p = .001), as well as TVR at
2 years (6.69 vs. 4.83%, HR: 1.40, 95% CI: 1.18–1.66, p < .001) (Table 2).
These differences in any revascularization and TVR were also observed at
30-day and 1-year follow-up, but not in the landmark analysis at 1 year.
3.2 | Treatment effect of antiplatelet therapy
according to presence/absence of bifurcation lesions
There were no significant differences in baseline characteristics
between experimental and reference groups stratified by pre-
sence/absence of bifurcation lesions (Table S1).
The results for the experimental versus reference antiplatelet treat-
ment in the bifurcation and nonbifurcation groups are reported in
Figure 2 and Table S2. Compared to the reference strategy, the experi-
mental strategy did not reduce the primary endpoint at 2 years in
patients undergoing PCI irrespective of the presence or absence of a
bifurcation lesion (bifurcation: HR: 0.74, 95% CI: 0.51–1.07; non-
bifurcation: HR: 0.90, 95% CI: 0.76–1.07, p for interaction = .343); how-
ever, it did result in a significant reduction in rates of definite or
probable ST at 2 years in patients in the bifurcation group (HR: 0.46,
95% CI: 0.22–0.97) versus nonbifurcation group (HR: 1.20, 95% CI:
0.85–1.69, p for interaction = .022) (Figure S1a). The same trend was
observed on 1-year definite or probable ST (p for interaction = .027),
whereas this significant benefit of ticagrelor monotherapy against aspi-
rin monotherapy subsided beyond 1 year (p for interaction = .482)
(Figure S1b). In terms of the 2-year incidence of stroke, the experimental
strategy showed a negative effect in patient undergoing bifurcation PCI
against the reference strategy (bifurcation: HR: 2.72, 95% CI: 1.06–6.94
in Figure S2a; nonbifurcation: HR: 0.82, 95% CI: 0.58–1.14, p for inter-
action = .018). This negative effect was observed at 1 year follow-up
(p for interaction = .021), but not at 30 days (p for interaction = .480)
and beyond 1 year (p for interaction = .479). In patients undergoing
bifurcation PCI, the majority of stroke was ischemic (experimental
F IGURE 1 Study flow chart
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group: 13/16 [81.2%], reference group: 6/6 [100%]), and the incidence
of ischemic stroke was not different between groups (experimental
group: 1.0% vs. reference group: 0.5%, HR 2.21, 95% CI: 0.84–5.80,
p = .109 in Figure S2b). Only three hemorrhagic strokes occurred in
patient undergoing bifurcation PCI, two occurred in the first year (days
135 and 139) and the third one beyond 1 year (day 596) (experimental
group: 0.2% vs. reference group: 0.0%, p = .081 in Figure S2c).
3.3 | Subgroup analysis of the primary endpoint in
patients treated for at least one bifurcation lesion
The subgroup analysis in patients with bifurcation PCI demonstrated
no variation in treatment effects for the primary endpoint according
to prespecified baseline characteristics as well as stenting technique
(one- vs. two-stent technique) (Figure 3). In patients treated with two-




n = 13,347 p Value
Age (years) 64.4 ± 10.4 64.6 ± 10.3 .601
Male 1950/2498 (78.1) 10,205/13347 (76.5) .082
Body mass index (kg/m2) 28.0 ± 4.5 28.2 ± 4.6 .034
Medical history
Diabetes mellitus 590/2495 (23.6) 3414/13339 (25.6) .040
Insulin-dependent diabetes mellitus 169/2490 (6.8) 1043/13308 (7.8) .071
Hypertension 1856/2491 (74.5) 9774/13300 (73.5) .289
Hypercholesterolemia 1722/2429 (70.9) 8965/12915 (69.4) .146
Current smoker 638/2498 (25.5) 3501/13347 (26.2) .471
Peripheral vascular disease 137/2469 (5.5) 857/13230 (6.5) .082
Chronic obstructive pulmonary disease 109/2482 (4.4) 702/13292 (5.3) .065
Previous major bleeding 15/2498 (0.6) 83/13326 (0.6) .896
Impaired renal functiona 322/2488 (12.9) 1836/13273 (13.8) .236
Previous stroke 70/2497 (2.8) 348/13325 (2.6) .584
Previous myocardial infarction 554/2494 (22.2) 3125/13305 (23.5) .167
Previous percutaneous coronary intervention 774/2498 (31.0) 4407/13333 (33.1) .043
Previous coronary artery bypass grafting 108/2498 (4.3) 830/13334 (6.2) <.001
Clinical presentation
Stable coronary artery disease 1277/2498 (51.1) 7127/13347 (53.4) .036
Acute coronary syndrome 1221/2498 (48.9) 6220/13347 (46.6) .036
Unstable angina 348/2498 (13.9) 1659/13347 (12.4) .038
Non-ST-elevation myocardial infarction 559/2498 (22.4) 2797/13347 (21.0) .110
ST-elevation myocardial infarction 314/2498 (12.6) 1764/13347 (13.2) .380
Procedural characteristics
Vascular access site
Femoral 679/2458 (27.6) 3589/13188 (27.2) .675
Brachial 15/2458 (0.6) 91/13188 (0.7) .658
Radial 1872/2458 (76.2) 9827/13188 (74.5) .085
Number of lesions treated 1.7 ± 0.9 1.4 ± 0.7 <.001
Number of stents 2.2 ± 1.4 1.6 ± 1.0 <.001
Total stent length 47.3 ± 31.6 33.2 ± 23.2 <.001
Randomization of antiplatelet therapy
Experimental treatment (1-month DAPT followed
by 23-month ticagrelor monotherapy)
1240/2498 (49.6) 6683/13347 (50.1) .692
Reference treatment (12-month DAPT followed
by 12-month aspirin monotherapy)
1258/2498 (50.4) 6664/13347 (49.9)
Note: Data are mean ± SD or counts (percentage).
Abbreviations: DAPT, dual antiplatelet therapy; ST, stent thrombosis.
aImpaired renal function is defined as estimated glomerular filtration rate of creatinine clearance of 60 mL/min per 1.73 m2 based on the Modification of
Diet in Renal Disease formula.
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n = 13,347 HR (95% CI) p Value
30-Day outcomes
All-cause death or new Q-wave MI 15 (0.60%) 61 (0.46%) 1.32 (0.75–2.31) .340
All-cause death 13 (0.52%) 54 (0.40%) 1.29 (0.70–2.36) .412
New Q-wave MI 2 (0.08%) 8 (0.06%) 1.34 (0.28–6.30) .712
Composite of all-cause death, stroke or new Q-wave MI 18 (0.72%) 86 (0.64%) 1.12 (0.67–1.86) .665
Stroke 3 (0.12%) 31 (0.23%) 0.52 (0.16–1.69) .267
Ischemic stroke 3 (0.12%) 23 (0.17%) 0.70 (0.21–2.32) .554
Any MI 38 (1.52%) 112 (0.84%) 1.82 (1.26–2.63) .001
Any revascularization 55 (2.20%) 189 (1.42%) 1.56 (1.16–2.11) .003
TVR 35 (1.40%) 124 (0.93%) 1.51 (1.04–2.20) .030
Definite ST 10 (0.40%) 49 (0.37%) 1.09 (0.55–2.15) .802
Definite or probable ST 16 (0.64%) 69 (0.52%) 1.24 (0.72–2.14) .439
BARC type 3 or 5 bleeding 16 (0.64%) 82 (0.61%) 1.04 (0.61–1.78) .876
1-Year outcomes
All-cause death or new Q-wave MI 67 (2.68%) 284 (2.13%) 1.27 (0.97–1.65) .082
All-cause death 40 (1.60%) 197 (1.48%) 1.09 (0.77–1.53) .630
New Q-wave MI 28 (1.12%) 89 (0.67%) 1.69 (1.10–2.58) .015
Composite of all-cause death, stroke, or new Q-wave MI 80 (3.20%) 352 (2.64%) 1.22 (0.95–1.55) .112
Stroke 15 (0.60%) 85 (0.64%) 0.94 (0.54–1.63) .833
Ischemic stroke 13 (0.52%) 67 (0.50%) 1.04 (0.57–1.88) .905
Any MI 64 (2.56%) 266 (1.99%) 1.29 (0.98–1.70) .064
Any revascularization 216 (8.65%) 828 (6.20%) 1.41 (1.22–1.64) <.001
TVR 125 (5.00%) 433 (3.24%) 1.55 (1.27–1.90) <.001
Definite ST 17 (0.68%) 77 (0.58%) 1.18 (0.70–2.00) .535
Definite or probable ST 24 (0.96%) 101 (0.76%) 1.27 (0.81–1.98) .291
BARC type 3 or 5 bleeding 50 (2.00%) 202 (1.51%) 1.33 (0.97–1.81) .073
2-Year outcomes
All-cause death or new Q-wave MI 118 (4.72%) 531 (3.98%) 1.19 (0.98–1.46) .083
All-cause death 75 (3.00%) 399 (2.99%) 1.01 (0.79–1.29) .964
New Q-wave MI 46 (1.84%) 139 (1.04%) 1.78 (1.27–2.48) .001
Composite of all-cause death, stroke or new Q-wave MI 138 (5.52%) 634 (4.75%) 1.17 (0.97–1.40) .100
Stroke 22 (0.88%) 138 (1.03%) 0.85 (0.54–1.34) .483
Ischemic stroke 19 (0.76%) 110 (0.82%) 0.92 (0.57–1.50) .746
Any MI 81 (3.24%) 405 (3.03%) 1.07 (0.85–1.36) .559
Any revascularization 280 (11.21%) 1,227 (9.19%) 1.24 (1.09–1.41) .001
TVR 167 (6.69%) 645 (4.83%) 1.40 (1.18–1.66) <.001
Definite ST 24 (0.96%) 104 (0.78%) 1.23 (0.79–1.92) .353
Definite or probable ST 32 (1.28%) 132 (0.99%) 1.30 (0.88–1.91) .188
BARC type 3 or 5 bleeding 62 (2.48%) 269 (2.02%) 1.23 (0.94–1.63) .134
Landmark analysis at 30 days
All-cause death or new Q-wave MI 103 (4.15%) 470 (3.54%) 1.18 (0.95–1.46) .134
All-cause death 62 (2.50%) 345 (2.60%) 0.96 (0.73–1.26) .776
New Q-wave MI 44 (1.77%) 131 (0.99%) 1.80 (1.28–2.54) .001
Composite of all-cause death, stroke, or new Q-wave MI 120 (4.86%) 548 (4.15%) 1.17 (0.96–1.43) .110
(Continues)
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stent technique, the experimental treatment was associated with a
numerically lower incidence of the primary endpoint at 2 years when
compared with the reference treatment, but not statistically signifi-
cant (4.6 vs. 9.1%, HR: 0.50, 95%CI: 0.24–1.02, p = .056).
4 | DISCUSSION
The main findings of the study are following:
1. PCI for bifurcation lesions with a biolimus A9-eluting stent was
not associated with higher incidence of primary endpoint of all-
cause death or new Q-wave MI compared with PCI for non-
bifurcation lesions, whereas significant difference was observed in
new Q-wave MI, any revascularization, and TVR at 2 years
between groups.
2. In patients who underwent bifurcation PCI, 1-month of DAPT
with aspirin and ticagrelor followed by 23-month ticagrelor mon-
otherapy had no impact on the primary endpoint but was associ-
ated with significant reduction in the risk of definite or probable
ST and significant excess of stroke compared with 12-month stan-
dard DAPT followed by 12-month aspirin monotherapy.
4.1 | Bifurcation group versus nonbifurcation group
In terms of the primary endpoint of death or new Q-wave MI, the
result of the study is in line with previously published data from all-
comers trials.1,20 In contrast, the higher rate of new Q-wave MI in the
bifurcation group over the nonbifurcation group was observed consis-
tently at 1- and 2-year follow-ups and in the landmark analysis at
1 year, whereas the incidence of any MI was similar between groups.
In the bifurcation subanalysis of the Resolute all-comers trial, 2-year
Q-wave MI rates in bifurcation and nonbifurcation groups were simi-
lar to the present trial, but there was no significant difference due to
less sample size (1.6% in bifurcation vs. 0.6% in nonbifurcation,
p = .097, n = 2,265).20 Therefore, this finding may suggest that bifur-
cation PCI can be associated with the occurrence of more severe MI
up to 2 years when compared with nonbifurcation PCI.
4.2 | Optimal duration of DAPT for patients
undergoing bifurcation PCI
The evidence for the optimal antiplatelet strategy after bifurcation
PCI is scarce, especially for potent antiplatelet drugs such as ticagrelor
and prasugrel. Recent pooled patient-level analysis demonstrated that





n = 13,347 HR (95% CI) p Value
Stroke 19 (0.77%) 107 (0.81%) 0.95 (0.58–1.54) .831
Ischemic stroke 16 (0.65%) 87 (0.66%) 0.98 (0.58–1.67) .948
Any MI 43 (1.76%) 293 (2.23%) 0.79 (0.57–1.09) .145
Any revascularization 225 (9.29%) 1,038 (7.96%) 1.18 (1.02–1.36) .025
TVR 132 (5.40%) 521 (3.98%) 1.37 (1.13–1.66) .001
Definite ST 14 (0.57%) 55 (0.42%) 1.36 (0.76–2.45) .301
Definite or probable ST 16 (0.65%) 63 (0.48%) 1.36 (0.78–2.35) .275
BARC type 3 or 5 bleeding 46 (1.87%) 187 (1.42%) 1.32 (0.96–1.82) .092
Landmark analysis at 1 year
All-cause death or new Q-wave MI 51 (2.10%) 247 (1.89%) 1.11 (0.82–1.50) .500
All-cause death 35 (1.43%) 202 (1.54%) 0.93 (0.65–1.33) .676
New Q-wave MI 18 (0.74%) 50 (0.38%) 1.94 (1.13–3.32) .014
Composite of all-cause death, stroke, or new Q-wave MI 58 (2.43%) 282 (2.20%) 1.10 (0.83–1.46) .492
Stroke 7 (0.29%) 53 (0.41%) 0.70 (0.32–1.55) .382
Ischemic stroke 6 (0.25%) 43 (0.33%) 0.75 (0.32–1.75) .498
Any MI 17 (0.72%) 139 (1.09%) 0.65 (0.40–1.08) .097
Any revascularization 64 (2.88%) 399 (3.28%) 0.87 (0.67–1.14) .318
TVR 42 (1.82%) 212 (1.69%) 1.07 (0.77–1.50) .672
Definite ST 7 (0.29%) 27 (0.21%) 1.39 (0.60–3.18) .440
Definite or probable ST 8 (0.33%) 31 (0.24%) 1.38 (0.63–3.00) .419
BARC type 3 or 5 bleeding 12 (0.50%) 67 (0.52%) 0.96 (0.52–1.78) .897
Note: Data are counts (percentage).
Abbreviations: BARC, Bleeding Academic Research Consortium; MI, myocardial infarction; POCE, patient-oriented composite endpoint; ST, stent
thrombosis; TVR, target vessel.
KOGAME ET AL. 7
1-year major adverse cardiac events mainly driven by MI, when com-
pared with prolonged DAPT of more than 1 year in patients undergo-
ing PCI for complex lesions including bifurcation lesions treated with a
two-stent technique.10 In addition, a multicenter observational study
reported that the risks of a composite of all-cause death or MI, MI,
and definite or probable ST at 4 years were significantly lower in the
prolonged (≥12 months) versus shorter DAPT group (<12 months)
after bifurcation PCI with drug-eluting stent (DES).21 From these
results, it seems that patients undergoing bifurcation PCI need at least
12 months of DAPT. The present study also shows no benefit of
1-month DAPT followed by ticagrelor monotherapy on the primary
endpoint when compared with 12-month DAPT.
4.3 | ST and stroke after bifurcation PCI
Previously coronary bifurcation lesions were reported as an indepen-
dent risk factor for ST22–24 as consequence of several factors. Firstly,
bifurcation stenting modifies local hemodynamics and creates low
endothelial shear stress and stagnant areas that could result in local
thrombogenicity.25 Secondly, pathological studies demonstrated that
the flow divider zone was associated with a high percentage of uncov-
ered struts and fibrin deposition several months after DES implanta-
tion, which could represent a substrate for ST.26 Thirdly, two-stent
strategies have been suspected of inducing overlapping device seg-
ments that could result in local thrombogenicity.27 Finally, bifurcation
stenting could also encourage stent malapposition due to vessel
dimension variation along the different segments and promote future
thrombotic events.28 In the present trial, the incidence of ST did not
statistically differ between bifurcation and nonbifurcation groups.
However, ticagrelor monotherapy following 1-month DAPT demon-
strated significant treatment effect on definite or probable ST at
2 years compared with conventional aspirin monotherapy following
12-month DAPT. This benefit was observed up to 1 year and subsided
beyond, although theoretically this benefit should be derived from the
comparison between ticagrelor monotherapy versus aspirin mon-
otherapy beyond 1 year. In addition, overall incidence of ST was quite
low, and the treatment effect of the experimental strategy on ST went
into opposite directions in bifurcation and nonbifurcation groups.
F IGURE 2 Treatment comparison of experimental versus reference antiplatelet strategy in randomized patients with versus without
bifurcation PCI at 1 year (A) and 2 years (B) follow-up. BARC, Bleeding Academic Research Consortium; MI, myocardial infarction;
PCI, percutaneous coronary intervention; ST, stent thrombosis; TVR, target vessel revascularization
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Consequently, these significant findings regarding ST can be consid-
ered as a play of chance.
On the other hand, in patients who underwent bifurcation PCI,
harmful effect of experimental treatment in 2-year stroke was
observed compared with reference treatment. This difference in
stroke was mainly derived from the result between 30 days and 1 year.
Therefore, procedure itself was probably not associated with the
occurrence of stroke. These findings may suggest that DAPT is associ-
ated with lower incidence of stroke up to 1 year compared with mon-
otherapy of ticagrelor. However, overall incidence of stroke was quite
low, and the treatment effect of the experimental strategy on stroke
went into opposite directions in bifurcation and nonbifurcation
groups. Consequently, these apparently significant findings regarding
stroke can be also considered as a play of chance similar to ST.
Regarding composite hard endpoint of all-cause death, stroke, or
new Q-wave MI at 2 years, there was no significant difference
between groups in patients undergoing bifurcation PCI, which sug-
gests that early discontinuation of aspirin at 30 days after bifurcation
PCI followed by ticagrelor monotherapy may be as safe as conven-
tional 12-month DAPT followed by aspirin monotherapy.
Further evidence from dedicated bifurcation trial testing 1-month
DAPT followed by P2Y12 monotherapy is warranted in order to fur-
ther elucidate that possible duality of effect (such as possible preven-
tion of ST and possible increase in stroke) in patients undergoing
bifurcation PCI.
4.4 | Study limitations
This prespecified subgroup analysis of primary endpoint has several
limitations.
Firstly, in the context of the overall trial in which the primary end-
point was not met, these findings need to be considered as hypothesis
generating.
Secondly, although this subgroup analysis of primary endpoint
was prespecified and information of bifurcation was prospectively
collected,12 no formal power calculation was performed. In addition,
there exist limitations inherent in subgroup analysis such as dimin-
ished power to detect real differences and increasing statistical likeli-
hood of false finding when many subgroups are examined with
F IGURE 2 (Continued)
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multiple testing. Therefore, the study findings should be considered as
hypothesis generating.29
Thirdly, clinical outcomes were not adjudicated by an independent
clinical event committee. All events were identified and confirmed by
the investigators of each hospital. There might be inaccuracies in
determining cause of death or target vessel MI. Therefore, we chose
all-cause death or new Q-wave MI centrally adjudicated by core lab
instead of cardiac death or target vessel MI as the primary outcome.
Nevertheless, the result of secondary endpoint should cautiously be
interpreted in conjunction with the individual components of the pri-
mary endpoint.
Fourthly, the analysis for comparing two- versus one-stent tech-
nique was postrandomization and nonprespecified analysis; therefore,
the findings are likely influenced by unmeasured confounders.
Fifthly, we did not collect the anatomic SYNTAX score including
Medina classification in all the patients, which limited the analysis
regarding anatomical complexity of each bifurcation lesion.
Finally, a biolimus A9-eluting stent has a relatively thicker strut of
120 μm compared with other current-generation DES. This might
result in worse outcomes in bifurcation lesions treated with two-stent
technique using a biolimus A9-eluting stent due to the overlap of rela-
tively thicker struts. A meta-analysis published in 2018 showed that
DES with ultrathin struts (strut thickness < 70 μm) reduced the
incidence of target lesion failure compared with that of contemporary
stents with thicker struts.30 However, in the present study, all patients
were exclusively treated with a biolimus A9-eluting stent, and this
makes the effect of antiplatelet drug more likely.
5 | CONCLUSIONS
After PCI for bifurcation lesions, using 1-month of DAPT followed by
ticagrelor monotherapy for 23 months did not demonstrate explicit
benefit regarding all-cause death or new Q-wave MI as in the overall
trial.
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